For the year ending 2025-12-31, CRSP made $3,510,000 in revenue. -$578,618,000 in net income. Net profit margin of -16484.84%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 3,510,000 | |||
| Research and development | 284,806,000 | |||
| Acquired in-process research and development | 96,253,000 | |||
| General and administrative | 73,542,000 | |||
| Collaboration expense, net | 213,480,000 | |||
| Total operating expenses | 668,081,000 | |||
| Loss from operations | -664,571,000 | |||
| Other income, net | 86,606,000 | |||
| Total other income, net | 86,606,000 | |||
| Net loss before income taxes | -577,965,000 | |||
| Provision for income taxes | 3,634,000 | |||
| Net loss | -581,599,000 | |||
| Foreign currency translation adjustment | 95,000 | |||
| Unrealized gain (loss) on marketable securities | 2,886,000 | |||
| Comprehensive loss | -578,618,000 | |||
| Basic net (loss) income per common share | -6.47 | |||
| Basic weighted-average common shares outstanding | 89,925,109 | |||
| Diluted net (loss) income per common share | -6.47 | |||
| Diluted weighted-average common shares outstanding | 89,925,109 | |||
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)